Atrás

Merck & Co., Inc.

Calidad de datos: 100%

MRK

NYSE Healthcare Drug Manufacturers - General

$119.37

▲ $3.00 (2.58%)

Cap. Mercado: 295.13B

Rango del Día

$116.74 $120.12

Rango de 52 Semanas

$73.31 $125.14

Volumen

6,937,576

Promedio 50D / 200D

$115.65 / $94.64

Cierre Anterior

$116.37

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica	Acción	Mediana del Sector
P/E	16.2	0.3
P/B	5.6	3.0
ROE %	36.9	3.7
Net Margin %	28.1	3.8
Rev Growth 5Y %	7.5	10.0
D/E	1.0	0.2

Precio Objetivo de Analistas

Hold

$128.54 +7.7%

Low: $100.00 High: $150.00

P/E Futuro

23.30

EPS Futuro

$5.12

Crecimiento EPS (est.)

+0.0%

Ingresos Est.

66.76B

Estimaciones de Ganancias

Período	EPS Est.	Ingresos Est.	Analistas
FY2030	$10.16 $9.87 – $10.37	74.13B	5
FY2029	$10.36 $10.07 – $10.58	74.56B	2
FY2028	$10.77 $8.85 – $13.13	74.79B	7

Earnings Surprises

Last 8 quarters

Quarter	Est. EPS	Actual EPS	Surprise
2026-02-03	$2.01	$2.04	+1.5%
2025-10-30	$2.36	$2.58	+9.3%
2025-07-29	$2.03	$2.13	+4.9%
2025-04-24	$2.13	$2.22	+4.2%
2025-02-04	$1.85	$1.72	-7.0%
2024-10-31	$1.50	$1.57	+4.7%
2024-07-30	$2.15	$2.28	+6.0%
2024-04-25	$1.88	$2.07	+10.1%

Insider Trading Activity

Buy ratio (90d) 0.0%

15 transactions

Date	Insider	Type	Shares	Price	Value
Feb 6, 2026	DeLuca Richard R. EVP&Pres, Merck Animal Heallth	sell	37,685	$120.92	$4,557,024.71
Feb 6, 2026	Oosthuizen Johannes Jacobus President, U.S. Market	sell	15,000	$121.87	$1,827,991.50
Jan 26, 2026	Litchfield Caroline EVP & CFO	grant	15,852	$107.40	$1,702,504.80
Jan 26, 2026	Guindo Chirfi Chief Marketing Officer	grant	9,865	$107.40	$1,059,501.00
Jan 26, 2026	Li Dean Y Executive VP & President, MRL	grant	20,469	$107.40	$2,198,370.60
Jan 26, 2026	Davis Robert M Chairman, CEO & President	grant	47,434	$107.40	$5,094,411.60
Dec 31, 2025	Seidman Christine E Director	grant	77	$105.26	$8,105.02
Nov 10, 2025	Downing Cristal N Chief Comm. & Public Afrs Ofcr	sell	7,085	$87.00	$616,395.00
Sep 30, 2025	Coe Mary Ellen Director	grant	357	$83.93	$29,963.01
Sep 30, 2025	Seidman Christine E Director	grant	97	$83.93	$8,141.21
Jun 30, 2025	GLOCER THOMAS H Director	grant	616	$79.16	$48,762.56
Jun 30, 2025	Seidman Christine E Director	grant	103	$79.16	$8,153.48
May 30, 2025	Craig Pamela J. Director	grant	2,863	$76.84	$219,992.92
May 30, 2025	Seidman Christine E Director	grant	2,863	$76.84	$219,992.92
Mar 31, 2025	Seidman Christine E Director	grant	91	$89.76	$8,168.16

Dividend History

7 yr streak

Yield

0.03%

Payout Ratio

0.45%

Growth (3Y)

5.42%

Growth (5Y)

5.75%

Ex-Date	Payment Date	Amount	Yield
Mar 16, 2026	Apr 07, 2026	$0.85	2.88%
Dec 15, 2025	Jan 08, 2026	$0.85	3.27%
Sep 15, 2025	Oct 07, 2025	$0.81	4.00%
Jun 16, 2025	Jul 08, 2025	$0.81	3.95%
Mar 17, 2025	Apr 07, 2025	$0.81	3.33%
Dec 16, 2024	Jan 08, 2025	$0.81	3.12%
Sep 16, 2024	Oct 07, 2024	$0.77	2.61%
Jun 17, 2024	Jul 08, 2024	$0.77	2.38%
Mar 14, 2024	Apr 05, 2024	$0.77	2.49%
Dec 14, 2023	Jan 08, 2024	$0.77	2.80%
Sep 14, 2023	Oct 06, 2023	$0.73	2.70%
Jun 14, 2023	Jul 10, 2023	$0.73	2.65%
Mar 14, 2023	Apr 10, 2023	$0.73	2.65%
Dec 14, 2022	Jan 09, 2023	$0.73	2.51%
Sep 14, 2022	Oct 07, 2022	$0.69	3.17%
Jun 14, 2022	Jul 08, 2022	$0.69	3.22%
Mar 14, 2022	Apr 07, 2022	$0.69	3.45%
Dec 14, 2021	Jan 07, 2022	$0.69	3.54%
Sep 14, 2021	Oct 07, 2021	$0.65	3.52%
Jun 14, 2021	Jul 07, 2021	$0.65	3.28%

Puntos Clave

Revenue grew 7.49% annually over 5 years — modest growth

ROE of 36.91% indicates high profitability

Net margin of 28.08% shows strong profitability

Generating 12.36B in free cash flow

Revenue growth is decelerating — 1Y growth trails 5Y average by 6.18%

Capital efficient — spends only 6.33% of revenue on capex

Crecimiento

Revenue Growth (5Y)

7.49%

Revenue (1Y)1.31%

Earnings (1Y)6.64%

FCF Growth (3Y)16.27%

Calidad

Return on Equity

36.91%

ROIC19.47%

Net Margin28.08%

Op. Margin41.19%

Seguridad

Debt / Equity

0.96

Current Ratio1.54

Interest Coverage0.00

Valoración

P/E Ratio

16.17

Forward P/E22.57

P/B Ratio5.61

EV/EBITDA12.36

Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	1.31%	Revenue Growth (3Y)	3.99%
Earnings Growth (1Y)	6.64%	Earnings Growth (3Y)	607.18%
Revenue Growth (5Y)	7.49%	Earnings Growth (5Y)	8.75%
Profitability
Revenue (TTM)	65.01B	Net Income (TTM)	18.25B
ROE	36.91%	ROA	13.34%
Gross Margin	81.50%	Operating Margin	41.19%
Net Margin	28.08%	Free Cash Flow (TTM)	12.36B
ROIC	19.47%	FCF Growth (3Y)	16.27%
Safety
Debt / Equity	0.96	Current Ratio	1.54
Interest Coverage	0.00
Dividends
Dividend Yield	0.03%	Payout Ratio	0.45%
Dividend Growth (3Y)	5.42%	Dividend Growth (5Y)	5.75%
Consecutive Div Years	7 yrs
Valuation
P/E Ratio	16.17	Forward P/E	22.57
P/B Ratio	5.61	P/S Ratio	4.54
PEG Ratio	1.88	Forward PEG	N/A
EV/EBITDA	12.36	Fwd EV/EBITDA	11.51
Forward P/S	4.42	Fwd Earnings Yield	4.43%
FCF Yield	4.19%
Market Cap	295.13B	Enterprise Value	331.10B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	65.01B	64.17B	60.12B	59.28B	48.70B
Net Income	18.25B	17.12B	365.00M	14.52B	13.05B
EPS (Diluted)	7.28	6.74	0.14	5.71	5.14
Gross Profit	52.98B	48.98B	43.99B	41.87B	35.08B
Operating Income	26.78B	20.22B	2.95B	18.28B	13.20B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	136.87B	117.11B	106.68B	109.16B	105.69B
Total Liabilities	84.20B	70.73B	69.04B	63.10B	67.44B
Shareholders' Equity	52.61B	46.31B	37.58B	45.99B	38.18B
Total Debt	50.53B	38.27B	36.27B	31.99B	34.63B
Cash & Equivalents	14.57B	13.24B	6.84B	12.69B	8.10B
Current Assets	43.52B	38.78B	32.17B	35.72B	30.27B
Current Liabilities	28.33B	28.42B	25.69B	24.24B	23.87B